Immunotherapy with autologous white cell infusions (“lymphocytes”) in the treatment of recurrent glioblastoma multiforme. A preliminary report

Published on Sep 1, 1977in Cancer5.742
· DOI :10.1002/1097-0142(197709)40:3<1037::AID-CNCR2820400311>3.0.CO;2-9
Harold F. Young49
Estimated H-index: 49
(MCV: VCU Medical Center),
Alan M. Kaplan12
Estimated H-index: 12
(MCV: VCU Medical Center),
William Regelson22
Estimated H-index: 22
(MCV: VCU Medical Center)
Autologous leukocytes (107 to 109), obtained with the Haemonetics's Leukaphoresis apparatus, were inoculated directly into recurrent glioblastoma tumors via indwelling catheters or by direct intratumoral injection through existing craniotomy openings. The rational use for autologous leukocyte (lymphocyte) infusions was based on in vitro autologous lymphocyte cytotoxicity to glioblastoma cells in the absence of serum inhibitory factors. Seven of 17 patients treated had life expectancy under 1 month; all patients had received definitive surgery, and all but two received radiation, nitrosourea chemotherapy and/or dexamethasone, and showed evidence of clinically recurrent disease. Following autologous leukocyte infusion (lymphocyte/granulocyte ratio 1:1), eight patients sustained clinical improvement and were alive up to 17 months later. No neurotoxicity ascribable to the procedure has been observed. One patient, who was comatose at the time of single leukocyte infusion, returned to full activity and lived for 17 months without an increase in tumor mass by brain scan. These results suggest that infusions of autologous leukocytes (lymphocyte-monocytes) directly into glioblastoma may be a viable additional treatment for glioblastoma and certainly warrants further evaluation.
📖 Papers frequently viewed together
36 Citations
188 Citations
32 Citations
#1Harold F. YoungH-Index: 49
#2R SakalasH-Index: 1
Last. A M KaplanH-Index: 1
view all 3 authors...
: The immunocompetence of patients with glioblastomas, but not patients with astrocytomas, is altered. In vitro testing demonstrates an inhibitory factor in the serum of patients with glioblastomas which impairs lymphocytic responsiveness. The degree of this impairment appears important in relation to the clinical course.
94 Citations
#1Young HfH-Index: 1
#2Sakalas RH-Index: 1
Last. Kaplan AmH-Index: 1
view all 3 authors...
18 Citations
#1Brooks WhH-Index: 1
#2Caldwell HdH-Index: 1
Last. Mortara RhH-Index: 1
view all 3 authors...
107 Citations
#1Jerzy Hildebrand (ULB: Université libre de Bruxelles)H-Index: 30
#2J. Brihaye (ULB: Université libre de Bruxelles)H-Index: 2
Last. Yvon Kenis (ULB: Université libre de Bruxelles)H-Index: 13
view all 5 authors...
Abstract Thirty-eight patients, 15 with recurrent primary brain tumors, 8 with breast carcinoma and 15 with lung carcinoma brain metastases were treated by a combination of 1-(2 -chloroethyl- 3 -cyclohexyl- 1 -nitrosourea) (CCNU): 100 mg/m 2 every 6 weeks; vincristine: 2 mg/m 2 and methotrexate: 24 mg/m 2 both given once a week for 4 weeks and subsequently once every 4 weeks. Dexamethasone: 10 mg/m 2 per day was initiated concomitantly with chemotherapy and administered for 4 weeks. Chemotherapy...
27 CitationsSource
35 Citations
#1Derek FewerH-Index: 7
#2Charles B. WilsonH-Index: 120
Last. Malcolm R. PowellH-Index: 4
view all 5 authors...
Eighty-one patients with recurrent primary or metastatic brain tumors were treated with carmustine (BCNU [1,3-Bis(2-chloroethyl)-1nitrosourea]) alone or carmustine and vincristine sulfate combined, and their responses analyzed. A response was defined as a clear clinical improvement unrelated to corticosteroid therapy. The overall response rate with carmustine was 48% and with the combination, 30%. In patients with glioblastoma, the response rates were 53% and 25%, respectively. The most responsi...
83 CitationsSource
#1Nelson L. LevyH-Index: 8
#2Mahaley MsH-Index: 10
Last. Eugene D. DayH-Index: 25
view all 3 authors...
Our studies showed that patients with primary intracranial neoplasms, both well differentiated and anaplastic, intra- and extracerebral, possessed peripheral blood lymphocytes that in vitro were specifically cytotoxic to tissue-cultured, autogenous tumor cells. Some studies suggested antigenic cross-reactivity between glioblastoma cells from different patients and, moreover, between glioblastoma and melanoma cells. One melanoma patient possessed lymphocytes cytotoxic to his tumor cells and to al...
91 Citations
Blood lymphocytes from tumor patients can specifically destroy cultivated neoplastic cells of the same histological origin as the tumors of the lymphocyte donors, irrespective of whether or not the donors have symptoms of growing tumor. The purpose of the present study was to investigate whether sera from tumor patients could block the cytotoxic effect of lymphocytes immune to the specific antigens of the respective neoplasms. A wide variety of tumors were included in the tests, namely malignant...
374 CitationsSource
157 CitationsSource
10 CitationsSource
Cited By73
#1Craig A Land (ETSU: East Tennessee State University)H-Index: 2
#2Phillip R. Musich (ETSU: East Tennessee State University)H-Index: 14
Last. Qian Xie (ETSU: East Tennessee State University)H-Index: 15
view all 5 authors...
Glioblastoma multiforme (GBM) is the most common malignant brain cancer that invades normal brain tissue and impedes surgical eradication, resulting in early local recurrence and high mortality. In addition, most therapeutic agents lack permeability across the blood brain barrier (BBB), further reducing the efficacy of chemotherapy. Thus, effective treatment against GBM requires tumor specific targets and efficient intracranial drug delivery. With the most recent advances in immunotherapy, genet...
8 CitationsSource
#1Joshua J. Loya (WSU: Wayne State University)H-Index: 5
#1Joshua Loya (WSU: Wayne State University)H-Index: 1
Last. Santosh KesariH-Index: 68
view all 5 authors...
Management of high-grade gliomas remains a complex challenge. Standard of care consists of microsurgical resection, chemotherapy and radiation, but despite these aggressive multimodality therapies the overall prognosis remains poor. A major focus of ongoing translational research studies is to develop novel therapeutic strategies that can maximize tumor cell eradication while minimizing collateral side effects. Particularly, biological intratumoral therapies have been the focus of new translatio...
1 CitationsSource
#1Catherine FloresH-Index: 11
#2Duane MitchellH-Index: 40
Glioblastoma multiforme (GBM) is the most common and most aggressive adult brain tumor with a patient median survival of 15 months from the time of diagnosis, and less than 20 weeks for patients with recurrent tumors. Current standard of care consists of multimodality therapy including image-guided tumor resection, fractionated radiotherapy, and chemotherapy. This aggressive therapy is non-specific and highly toxic, leaving collateral damage to surrounding normal brain and systemic tissue, and i...
#1Antonio DagaH-Index: 33
#2Cristina Bottino (Istituto Giannina Gaslini)H-Index: 83
Last. Silvano FerriniH-Index: 67
view all 5 authors...
Glioblastoma (GBM) is a deadly tumor, which in spite of surgery and radio/chemotherapy frequently undergoes relapses related to the infiltration of the normal parenchyma and to resistance to cytotoxic and radiation therapy. Immunotherapy may represent a promising approach, which may complement existing therapies with the aim of eliminating residual tumor cells, through their selective targeting by immune effector cells or antibodies. This goal can be achieved through different approaches, based ...
21 CitationsSource
#1Kevin ChowH-Index: 8
#2Stephen Gottschalk (BCM: Baylor College of Medicine)H-Index: 55
The outcome for patients with the most common primary brain tumor, glioblastoma multiforme (GBM), remains poor. Several immunotherapeutic approaches are actively being pursued including antibodies and cell-based therapies. While the blood–brain barrier protects brain tumor cells from therapeutic antibodies, immune cells have the ability to traverse the blood–brain barrier and migrate into GBM tumors to exert their therapeutic function. Results of Phase I clinical studies with vaccines to induce ...
26 CitationsSource
#1Enrico C. Lallana (Dartmouth–Hitchcock Medical Center)H-Index: 1
#2William F. Hickey (Dartmouth–Hitchcock Medical Center)H-Index: 51
Last. Camilo E. Fadul (Dartmouth–Hitchcock Medical Center)H-Index: 29
view all 3 authors...
Decreased immune surveillance is thought to be one of the mechanisms by which neoplastic cells are able to thrive. When cancer is located in the nervous system, an immune privileged site, its ability to evade detection, and targeting by immune cells may contribute to its aggressive behavior. Furthermore, high-grade gliomas, the most frequent and lethal primary brain tumors, induce both a local and systemic state of immune suppression that hampers efforts to manipulate the immune system as an eff...
#1Duane Mitchell (Duke University)H-Index: 40
#2John H. Sampson (Duke University)H-Index: 94
The immunologic treatment of cancer has long been heralded as a targeted molecular therapeutic with the promise of eradicating tumor cells with minimal damage to surrounding normal tissues. However, a demonstrative example of the efficacy of immunotherapy in modulating cancer progression is still lacking for most human cancers. Recent breakthroughs in our understanding of the mechanisms leading to full T-cell activation, and recognition of the importance of overcoming tumor-induced immunosuppres...
33 CitationsSource
#1Duane Mitchell (Duke University)H-Index: 40
#2Peter E. Fecci (Harvard University)H-Index: 28
Last. John H. Sampson (Duke University)H-Index: 94
view all 3 authors...
Despite aggressive multi-modality therapy including surgery, radiation, and chemotherapy, the prognosis for patients with malignant primary brain tumors remains very poor. Moreover, the non-specific nature of conventional therapy for brain tumors often results in incapacitating damage to surrounding normal brain and systemic tissues. Thus, there is an urgent need for the development of therapeutic strategies that precisely target tumor cells while minimizing collateral damage to neighboring eloq...
81 CitationsSource
#1Peter C. HuszthyH-Index: 16
view all 1 authors...